相关实验视频

Updated: Sep 13, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

在非小细胞肺癌中复合EGFR突变的临床结果:一项全国性,回顾性,多中心研究

Lina Atlagh¹, Anne-Claire Toublanc², Benoit Roch³

¹Pneumology Department, University Hospital Center of Limoges, Limoges, France.

Clinical lung cancer

|July 26, 2025

概括

这项研究表明,氨酸激酶抑制剂 (TKIs) 改善了非小细胞肺癌 (NSCLC) 患者的结局,这些患者具有复合EGFR突变. 这些突变的基于结构的分类可以指导一线TKI选择以获得更好的治疗反应.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
药理学药理学是指药理学的学科.

背景情况:

复合表皮生长因子受体 (EGFR) 突变在非小细胞肺癌 (NSCLC) 中很罕见.
对具有复合EGFR突变的NSCLC的最佳治疗策略尚不清楚.
基于EGFR突变的新型体外结构分类显示出预测治疗反应的前景.

研究的目的:

为了评估患有先进NSCLC携带EGFR复合突变的患者的临床结果.
根据基于EGFR突变的结构分类来评估不同治疗策略的疗效.
确定基于结构的EGFR突变分类对整体存活率 (OS) 和无进展存活率 (PFS) 的影响.

主要方法:

一项多中心,回顾性,全国性的研究包括81名患有晚期NSCLC和复合EGFR突变的患者 (不包括T790M和外显子20插入).
患者的瘤根据基于结构的系统进行分类:经典突变,P环和αC螺旋压缩 (PACC) 突变或未分类突变.
根据突变分类和接受的治疗,分析了总生存率 (OS) 和无进展生存率 (PFS).

主要成果:

在基于结构的组中,中位 OS 显著不同 (未分类的69.5 个月,经典的47 个月,PACC 突变的24.3 个月;P = .01).
作为一线治疗的铁激酶抑制剂 (TKIs) 与化疗 (7.1个月;P = .005) 相比,导致更长的中位数PFS (12.6个月).
在PACC组中,与其他治疗方法相比, osimertinib 改善了 PFS (HR 0.34; P=.027).

结论:

用TKIs治疗与EGFR复合突变患者的良好结果有关.
基于EGFR突变的结构分类可能有助于为NSCLC患者选择合适的第一线TKIs.
这种分类系统为这个具有挑战性的患者群体提供了个性化治疗策略的潜在框架.

关键词:

经典的EGFR突变可以说是EGFR突变.复合突变是一种复合突变.PACC EGFR 的突变罕见的EGFR突变铁氨酸激酶抑制剂铁氨酸激酶抑制剂

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...